top of page
Elderly Care Interaction

Alzheimer's Disease 

What is Alzheimer's Disease?

Alzheimer’s is a progressive brain disease that leads to dementia and affects memory, thinking and behavior. Symptoms eventually become severe enough to interfere with daily tasks. Alzheimer’s is not just a normal part of aging, although the majority of people with Alzheimer’s are 65 and older. Risk factors such as aging, genetics, and lifestyle, can lead to destructive processes to the cells in the brain, including neurons and the cells that support the neurons, called glial cells. This damage can induce inflammation and interfere with the ability of glial cells to perform normal functions, such as supplying energy to the brain.

​

There is currently no cure for Alzheimer’s Disease. Therapies that treat the underlying disease process and reduce inflammation hold promise to slow the worsening of dementia symptoms and improve quality of life for those with Alzheimer’s and their caregivers.

SIGNAL-AD logo in purple and green

NCT04381468

Sponsor: Vaccinex Inc.

Completed

SIGNAL-AD Alzheimer's Disease

Evaluating the Safety and Efficacy of our drug Pepinemab in Patients with Alzheimer’s Disease.
Phase 1b/2

Condition(s): Alzheimer Disease (AD)

Collaborators: Alzheimer's Association, Alzheimer's Drug Discovery Foundation

Trial Purpose

The purpose of the study is to investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in people with early AD dementia (early AD). The primary hypothesis being tested is whether pepinemab will be safe and provide benefits in clinical assessments of cognition and in brain metabolism as measured by FDG-PET.

a map of the united states where states are colored gray if no site available or purple if there is a site.  Cities are highlighted by green dots.

Trial Details

About the Trial

All patients who enroll in the trial will receive treatment once each month by intravenous infusion.

​

Phase

Phase 1b/Phase 2

​

Dates

Study Start Date:  July 22, 2021

Primary Completion Date: June 5, 2024

Study Completion Date: June 5, 2024

​

Products

pepinemab

placebo

55 to 85

Age(s)

Alzheimer's Disease

(MMSE range 17-26)
Conditions(s)

All

Genders(s)

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

bottom of page